Pretax income is the income that a company earns before paying income taxes. ATAI Life Sciences NV's pretax income for the
three
months ended in Mar. 2024 was $-25.68 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-31.81 Mil.
ATAI Life Sciences NV's pretax margin was %.
During the past 5 years, ATAI Life Sciences NV's highest Pretax Margin was -670.40%. The lowest was -58018.03%. And the median was -12511.46%.
ATAI Life Sciences NV Pre-Tax Income Historical Data
The historical data trend for ATAI Life Sciences NV's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ATAI Life Sciences NV's Pre-Tax Income
For the Biotechnology subindustry, ATAI Life Sciences NV's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ATAI Life Sciences NV's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where ATAI Life Sciences NV's Pre-Tax Income falls into.
ATAI Life Sciences NV Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
ATAI Life Sciences NV's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATAI Life Sciences NV (NAS:ATAI) Pre-Tax Income Explanation
ATAI Life Sciences NV's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 5 years, ATAI Life Sciences NV's highest Pretax Margin was -670.40%. The lowest was -58018.03%. And the median was -12511.46%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATAI Life Sciences NV Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of ATAI Life Sciences NV's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
ATAI Life Sciences NV (ATAI Life Sciences NV) Business Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATAI has been successfully added to your 